학술논문
Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone
Document Type
article
Author
Masanori Asakura; Jiyoong Kim; Hiroshi Asanuma; Yasuharu Nakama; Kengo Tsukahara; Yorihiko Higashino; Tetsuya Ishikawa; Shinji Koba; Mitsuru Tsujimoto; Hideo Himeno; Yasuyuki Maruyama; Takanori Ookusa; Shunichi Yoda; Hiroshi Suzuki; Shinji Okubo; Makoto Shimizu; Yuji Hashimoto; Kazuo Satake; Susumu Fujino; Hiroyasu Uzui; Yoshiyuki Nagai; Tohru Kohno; Sumio Mizuno; Makoto Nakahama; Hounin Kanaya; Toyoaki Murohara; Kazuki Fukui; Hiroyuki Takase; Nobuyuki Ohte; Takaaki Shiono; Masatake Fukunami; Tsutomu Endo; Reimin Sawada; Kenshi Fujii; Motoshi Takeuchi; Shuntaro Ikeda; Koichi Mizuno; Masaaki Uematsu; Taku Matsubara; Shoji Yano; Jun Takahashi; Kousei Ueda; Yoshihiko Kinoshita; Koichi Tamita; Hideki Hayashi; Toshimitsu Hamasaki; Masafumi Kitakaze
Source
EClinicalMedicine, Vol 4, Iss , Pp 10-24 (2018)
Subject
Language
English
ISSN
2589-5370
Abstract
Background: Secondary prevention in patients with myocardial infarction (MI) is critically important to prevent ischaemic heart failure and reduce social burden. Pioglitazone improves vascular dysfunction and prevents coronary atherosclerosis, mainly via anti-inflammatory and antiatherogenic effects by enhancing adiponectin production in addition to antihyperglycemic effects, thus suggesting that pioglitazone attenuates cardiovascular events in patients with mild (HbA1c levels